824 Synergistic effects of a therapeutic cancer vaccine, an immunocytokine, and an HDAC inhibitor in an HPV tumor model

824 Synergistic effects of a therapeutic cancer vaccine, an immunocytokine, and an HDAC inhibitor in an HPV tumor model

Bibliographic Details
Main Authors:	Jeffrey Schlom, Lisa K Poppe, Nicholas Roller, Miriam Marlene Medina-Enríquez, Caroline Jochems Frohlich
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
by: Samuel T. Pellom, et al.
Published: (2021-04-01)

NHS-IL12, a Tumor-Targeting Immunocytokine
by: Greiner JW, et al.
Published: (2021-05-01)

Immunocytokines
by: Katrin L. Gutbrodt, et al.
Published: (2012-05-01)

Therapeutic Vaccines for HPV-Associated Malignancies
by: Smalley Rumfield C, et al.
Published: (2020-10-01)

Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
by: Christine M. Minnar, et al.
Published: (2024-01-01)

Immunocytokines with activity-on-demand by combination with small molecule inhibitors
by: Dafne Müller
Published: (2024-03-01)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
by: Y. Maurice Morillon, et al.
Published: (2019-06-01)

Utilizing Immunocytokines for Cancer Therapy
by: Erin Runbeck, et al.
Published: (2021-03-01)

375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
by: Jeffrey Schlom, et al.
Published: (2020-11-01)

1063 Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12
by: Renee N Donahue, et al.
Published: (2023-11-01)

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
by: Giulia Rotta, et al.
Published: (2024-03-01)

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.
by: Michele Cea, et al.
Published: (2011-01-01)

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
by: Tzeng, Alice, et al.
Published: (2015)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
by: Margaret E. Gatti-Mays, et al.
Published: (2021-03-01)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
by: Lourdes Hontecillas-Prieto, et al.
Published: (2020-09-01)

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
by: Qinglang Mei, et al.
Published: (2023-09-01)

Immunocytokines: a review of molecules in clinical development for cancer therapy
by: List T, et al.
Published: (2013-08-01)

A possible link to uracil DNA glycosylase in the synergistic action of HDAC inhibitors and thymidylate synthase inhibitors
by: Meredith S. Showler, et al.
Published: (2020-10-01)

Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
by: Maria Mrakovcic, et al.
Published: (2019-12-01)

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling
by: Yusuke Shibuya, et al.
Published: (2023-02-01)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
by: Lukman O. Afolabi, et al.
Published: (2021-08-01)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
by: Renee N Donahue, et al.
Published: (2022-04-01)

HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
by: Hongbiao Huang, et al.
Published: (2012-01-01)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
by: Keunok Jung, et al.
Published: (2022-10-01)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
by: Melissa Paoloni, et al.
Published: (2015-01-01)

The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis
by: Tsz Ki Wang, et al.
Published: (2023-06-01)

Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression
by: Cai-Ping Chen, et al.
Published: (2019-09-01)

6.824 Distributed Computer Systems, Fall 2002
by: Morris, Robert Tappan
Published: (2002)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
by: Jacob King, et al.
Published: (2021-11-01)

1159 A targeted masked ImmunoCytokine for CD138 expressing cancers
by: Ryan Trinh, et al.
Published: (2023-11-01)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
by: Christian Schrenk, et al.
Published: (2023-03-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01)

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
by: Yuting Wang, et al.
Published: (2020-04-01)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
by: Christian Klein, et al.
Published: (2017-03-01)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
by: Zsófia Kutil, et al.
Published: (2019-11-01)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
by: Siyu Gu, et al.
Published: (2023-02-01)

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
by: Maria Mrakovcic, et al.
Published: (2019-05-01)

The synergistic effect of PKA activator and HDAC inhibitor to reactivate HIV-1 provirus from latently infected cells
by: B.S. Choi, et al.
Published: (2015-12-01)

483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers
by: Jeffrey Schlom, et al.
Published: (2021-11-01)

Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
by: Maciej Kujawski, et al.
Published: (2020-01-01)